Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years

2003 ◽  
Vol 48 (12) ◽  
pp. 3522-3531 ◽  
Author(s):  
Dirk M. Nuenninghoff ◽  
Gene G. Hunder ◽  
Teresa J. H. Christianson ◽  
Robyn L. McClelland ◽  
Eric L. Matteson
Keyword(s):  
Aortic Aneurysm ◽  
Aortic Dissection ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Population Based ◽  
Artery Stenosis ◽  
Large Artery ◽  
Population Based Study

scholarly journals Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis

2012 ◽  
Vol 72 (12) ◽  
pp. 1989-1994 ◽  
Author(s):  
Tanaz A Kermani ◽  
Kenneth J Warrington ◽  
Cynthia S Crowson ◽  
Steven R Ytterberg ◽  
Gene G Hunder ◽  
...  
Keyword(s):  
Aortic Aneurysm ◽  
General Population ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Population Based ◽  
Artery Stenosis ◽  
Large Vessel ◽  
Large Artery ◽  
Incidence Trends ◽  
Aneurysm Dissection

ObjectivesTo evaluate incidence-trends and timing of large-vessel (LV) manifestations in patients with giant cell arteritis (GCA), and to examine the influence of LV manifestations on survival.MethodsA population-based incident cohort of patients diagnosed with GCA between 1950 and 2004 was used. LV involvement was defined as large-artery stenosis or aortic aneurysm/dissection that developed in the 1 year before GCA diagnosis or at any time thereafter. Patients were followed up until death or 31 December 2009.ResultsThe study included 204 patients, 80% women, mean age at diagnosis of GCA 76.0 years (±8.2 years). Median length of follow-up was 8.8 years. The cumulative incidence of any LV manifestation at 10 years was 24.9% for patients diagnosed with GCA between 1980 and 2004 compared with 8.3% for patients diagnosed with GCA between 1950 and 1979. The incidence of any LV event was high within the first year of GCA diagnosis. The incidence of aortic aneurysm/dissection increased 5 years after GCA diagnosis. Compared with the general population, survival was decreased in patients with an aortic aneurysm/dissection (standardized mortality ratio (SMR) 2.63; 95% CI 1.78 to 3.73) but not in patients with large-artery stenosis (SMR 1.44; 95% CI 0.87 to 2.25). Patients with GCA and aortic manifestations had a higher than expected number of deaths from cardiovascular and pulmonary causes than the general population. Among patients with GCA, aortic manifestations were associated with increased mortality (HR=3.4; 95% CI 2.2 to 5.4).ConclusionsVigilance and screening for aortic aneurysms should be considered in all patients 5 years after the incidence of GCA. Aortic aneurysm/dissection is associated with increased mortality in GCA.

Aortic dissection in giant cell arteritis: A population-based study of predictors

2013 ◽  
Vol 42 (4) ◽  
pp. 721-722
Author(s):  
T. Kermani ◽  
K. Warrington ◽  
C. Crowson ◽  
G. Hunder ◽  
S. Ytterberg ◽  
...  
Keyword(s):  
Aortic Dissection ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Population Based ◽  
Population Based Study

Giant cell arteritis and inflammatory bowel disease – Is there a connection? Results from a population-based study

2018 ◽  
Vol 17 (11) ◽  
pp. 1134-1137 ◽  
Author(s):  
Yarden Yavne ◽  
Shmuel Tiosano ◽  
Dana Ben-Ami ◽  
Abdulla Watad ◽  
Adi Guy ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Bowel Disease ◽  
Population Based ◽  
Population Based Study ◽  
Inflammatory Bowel

scholarly journals Visual Complications in Patients with Biopsy-proven Giant Cell Arteritis: A Population-based Study

2016 ◽  
Vol 43 (8) ◽  
pp. 1559-1565 ◽  
Author(s):  
Muna Saleh ◽  
Carl Turesson ◽  
Martin Englund ◽  
Peter A. Merkel ◽  
Aladdin J. Mohammad
Keyword(s):  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Inflammatory Responses ◽  
Temporal Artery ◽  
Reference Population ◽  
Population Based ◽  
Population Based Study ◽  
Protein Levels ◽  
Reactive Protein ◽  
Background Population

Objective.To study the clinical and laboratory characteristics of patients with biopsy-proven giant cell arteritis (GCA) with visual complications, and to evaluate the incidence rate of visual complications in GCA compared to the background population.Methods.Data from 840 patients with GCA in the county of Skåne, Sweden, diagnosed between 1997 and 2010, were used for this analysis. Cases with visual complications were identified from a diagnosis registry and confirmed by a review of medical records. The rate of visual complications in patients with GCA was compared with an age- and sex-matched reference population.Results.There were 85 patients (10%) who developed ≥ 1 visual complication after the onset of GCA. Of the patients, 18 (21%) developed unilateral or bilateral complete visual loss. The mean age at diagnosis was 78 years (± 7.3); 69% were women. Compared with patients without visual complications, those with visual complication had lower C-reactive protein levels at diagnosis and were less likely to have headache, fever, and palpable abnormal temporal artery. The use of β-adrenergic inhibitors was associated with visual complications. The incidence of visual complications among patients with GCA was 20.9/1000 person-years of followup compared to 6.9/1000 person-years in the reference population, resulting in a rate ratio of 3.0 (95% CI 2.3–3.8).Conclusion.Ten percent of patients with GCA developed visual complications, a rate substantially higher than that of the general population. Patients with GCA who had visual complications had lower inflammatory responses and were more likely to have been treated with β-adrenergic inhibitors compared with patients without visual complications.

scholarly journals SAT0252 INCREASED MORTALITY FOR INDIVIDUALS WITH GIANT CELL ARTERITIS: A POPULATION-BASED STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1069.1-1069
Author(s):  
L. Barra ◽  
J. Pope ◽  
P. Pequeno ◽  
J. Gatley ◽  
J. Widdifield
Keyword(s):  
General Population ◽  
Giant Cell Arteritis ◽  
Giant Cell ◽  
Age Groups ◽  
Mortality Rates ◽  
Population Based ◽  
Population Based Study ◽  
Risk Of Mortality ◽  
Younger Age ◽  
Over Time

Background:Individuals with giant cell arteritis (GCA) are at increased risk of serious morbidity including cardiovascular disease and stroke. Yet the risk of mortality among individuals with GCA have produced conflicting reports1.Objectives:Our aim was to evaluate excess all-cause mortality among individuals with GCA relative to the general population over time.Methods:We performed a population-based study in Ontario, Canada, using health administrative data among all individuals 50 years and older. Individuals with GCA were identified using a validated case definition (81% PPV, 100% specificity). All Ontario residents aged 50 and above who do not have GCA served as the General Population comparators. Deaths occurring in each cohort each year were ascertained from vital statistics. Annual crude and age/sex standardized all-cause mortality rates were determined for individuals with and without GCA between 2000 and 2018. Standardized mortality ratios (SMRs) were calculated to measure relative excess mortality over time. Differences in mortality between sexes and ages were also evaluated.Results:Population denominators among individuals 50 years and older with GCA and the General Population increased over time with 12,792 GCA patients and 5,456,966 comparators by 2018. Annual standardized mortality rates among the comparators steadily declined over time and were significantly lower than GCA morality rates (Figure). Annual GCA mortality rates fluctuated between 42-61 deaths per 1000 population (with overlapping confidence intervals) during the same time period. SMRs for GCA ranged from 1.28 (95% CI 1.08,1.47) at the lowest in 2002 to 1.96 (95% CI 1.84, 2.07) at the highest in 2018. GCA mortality rates and SMRs were highest among males and younger age groups.Conclusion:Over a 19-year period, mortality has remained increased among GCA patients relative to the general population. GCA mortality rates were higher among males and more premature deaths were occurring at younger age groups. In our study, improvements to the relative excess mortality for GCA patients over time (mortality gap) did not occur. Understanding cause-specific mortality and other factors are necessary to inform contributors to premature mortality among GCA patients.References:[1]Hill CL, et al. Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):513-9.Figure.Acknowledgments: :This study was supported by a CIORA grantDisclosure of Interests:Lillian Barra: None declared, Janet Pope Grant/research support from: AbbVie, Bristol-Myers Squibb, Eli Lilly & Company, Merck, Roche, Seattle Genetics, UCB, Consultant of: AbbVie, Actelion, Amgen, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eicos Sciences, Eli Lilly & Company, Emerald, Gilead Sciences, Inc., Janssen, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB, Speakers bureau: UCB, Priscila Pequeno: None declared, Jodi Gatley: None declared, Jessica Widdifield: None declared

Sign in / Sign up

Export Citation Format

Share Document